dc.contributor.author |
Novitsky, V. |
|
dc.contributor.author |
Wang, R. |
|
dc.contributor.author |
Bussmann, H. |
|
dc.contributor.author |
Lockman, S. |
|
dc.contributor.author |
Baum, M. |
|
dc.contributor.author |
Shapiro, R. |
|
dc.contributor.author |
Thior, I. |
|
dc.contributor.author |
Wester, C. |
|
dc.contributor.author |
Wester, C.W. |
|
dc.contributor.author |
Ogwu, A. |
|
dc.contributor.author |
Asmelash, A. |
|
dc.contributor.author |
Musonda, R. |
|
dc.contributor.author |
Campa, A. |
|
dc.contributor.author |
Moyo, S. |
|
dc.contributor.author |
van Widenfelt, E. |
|
dc.contributor.author |
Mine, M. |
|
dc.contributor.author |
Moffat, C. |
|
dc.contributor.author |
Mmalane, M. |
|
dc.contributor.author |
Makhema, J. |
|
dc.contributor.author |
Marlink, R. |
|
dc.contributor.author |
Gilbert, P. |
|
dc.contributor.author |
DeGruttola, V. |
|
dc.contributor.author |
Essex, M. |
|
dc.date.accessioned |
2013-04-17T14:58:07Z |
|
dc.date.available |
2013-04-17T14:58:07Z |
|
dc.date.issued |
2010 |
|
dc.identifier.other |
doi: 10.1371/journal.pone.0010148. |
|
dc.identifier.other |
doi:10.1371/journal.pone.0010148 |
|
dc.identifier.uri |
http://hdl.handle.net/123456789/855 |
|
dc.description.abstract |
The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naïve HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1-4.2 log(10)) and cART-initiating cohorts (5.1-5.3 log(10)) by about one log(10). The proportion of individuals with high (> or = 50,000 (4.7 log(10)) copies/ml) HIV-1 RNA levels ranged from 24%-28% in the general HIV-positive population cohorts to 65%-83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%-50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load > or = 50,000 (4.7 log(10)) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%-82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified "test-and-treat" strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities. |
en_GB |
dc.language.iso |
en |
en_GB |
dc.relation.ispartofseries |
PLoS One. 2010;5(4):e10148. |
|
dc.subject |
HIV-1 subtype |
en_GB |
dc.subject |
C-infected individuals |
en_GB |
dc.title |
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. |
en_GB |
dc.type |
Article |
en_GB |